Expression profile of SARS-CoV-2 cellular entry proteins in normal oral mucosa and oral squamous cell carcinoma.


Journal

Clinical and experimental dental research
ISSN: 2057-4347
Titre abrégé: Clin Exp Dent Res
Pays: United States
ID NLM: 101692332

Informations de publication

Date de publication:
02 2022
Historique:
revised: 29 04 2021
received: 09 09 2020
accepted: 02 10 2021
pubmed: 3 11 2021
medline: 31 3 2022
entrez: 2 11 2021
Statut: ppublish

Résumé

Besides angiotensin converting enzyme 2 (ACE2), an active involvement of proteases (FURIN and/or TMPRSS2) is important for cellular entry of SARS-CoV-2. Therefore, a simultaneous expression profiling of entry proteins in a tissue might provide a better risk assessment of SARS-CoV-2 infection as compared to individual proteins. In an attempt to understand the relative susceptibility of oral squamous cell carcinoma (OSCC) lesions as compared to the normal oral mucosa (NOM) for SARS-CoV-2 attachment/entry, this study examined the mRNA and protein expression profiles of ACE2, FURIN, and TMPRSS2 in the corresponding tissues using public transcriptomic and proteomics datasets. Public transcriptomic and proteomics datasets (the Cancer Genome Atlas (TCGA)/the Genotype-Tissue Expression (GTEx), the Human Protein Atlas (HPA), and two independent microarray datasets) were used to examine the expression profiles of ACE2, TMPRSS2 and FURIN in NOM and OSCC. ACE2, TMPRSS2, and FURIN mRNAs were detected in NOM, however, at lower levels as compared to other body tissues. Except for moderate up-regulation of FURIN, expression levels of ACE2 and TMPRSS2 mRNA were unchanged/down-regulated in OSCC as compared to the NOM. These results indicate that NOM may serve as a possible site for SARS-CoV-2 attachment, however, to a lesser extent as compared to organs with higher expression levels of the SARS-CoV-2 entry proteins. However, the evidence is lacking to suggest that expression status of entry proteins predisposes OSCC lesions to additional risk for SARS-CoV-2 attachment/entry as compared to NOM.

Identifiants

pubmed: 34726347
doi: 10.1002/cre2.510
pmc: PMC8653086
doi:

Substances chimiques

RNA, Messenger 0
ACE2 protein, human EC 3.4.17.23
Angiotensin-Converting Enzyme 2 EC 3.4.17.23
Serine Endopeptidases EC 3.4.21.-
TMPRSS2 protein, human EC 3.4.21.-
FURIN protein, human EC 3.4.21.75
Furin EC 3.4.21.75

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

117-122

Subventions

Organisme : Faculty of Dentistry, University of Oslo

Informations de copyright

© 2021 The Authors. Clinical and Experimental Dental Research published by John Wiley & Sons Ltd.

Références

Clin Exp Dent Res. 2022 Feb;8(1):117-122
pubmed: 34726347
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102
pubmed: 28407145
Lancet. 2020 Jun 20;395(10241):1919-1926
pubmed: 32473682
Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2152-62
pubmed: 18669583
J Pathol. 2004 Jun;203(2):631-7
pubmed: 15141377
Proc Natl Acad Sci U S A. 2020 May 26;117(21):11727-11734
pubmed: 32376634
Nat Rev Microbiol. 2009 Jun;7(6):439-50
pubmed: 19430490
Mol Cancer. 2020 Apr 28;19(1):80
pubmed: 32345328
Front Med. 2020 Apr;14(2):185-192
pubmed: 32170560
J Dent Res. 2020 Sep;99(10):1120-1121
pubmed: 32479133
Nature. 2014 Mar 27;507(7493):462-70
pubmed: 24670764
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Clin Cancer Res. 2004 Jul 1;10(13):4480-8
pubmed: 15240540
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
PLoS One. 2012;7(4):e35276
pubmed: 22530001
Mol Cell. 2020 May 21;78(4):779-784.e5
pubmed: 32362314
JAMA Oncol. 2020 Jul 1;6(7):1108-1110
pubmed: 32211820
Lancet Oncol. 2020 Jul;21(7):893-903
pubmed: 32479790
Nat Commun. 2017 Oct 20;8(1):1077
pubmed: 29057876
Med Hypotheses. 2020 Nov;144:109987
pubmed: 32562913
Science. 2015 May 8;348(6235):648-60
pubmed: 25954001
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Int J Oral Sci. 2020 Feb 24;12(1):8
pubmed: 32094336

Auteurs

Dipak Sapkota (D)

Department of Oral Biology, Faculty of Dentistry, University of Oslo, Oslo, Norway.

Sunita Sharma (S)

Department of Oral Biology, Faculty of Dentistry, University of Oslo, Oslo, Norway.

Tine M Søland (TM)

Department of Oral Biology, Faculty of Dentistry, University of Oslo, Oslo, Norway.
Department of Pathology, Rikshospitalet, Oslo University Hospital, Oslo, Norway.

Paulo H Braz-Silva (PH)

Department of Stomatology, School of Dentistry, University of São Paulo, São Paulo, Brazil.
Laboratory of Virology, Institute of Tropical Medicine of São Paulo, School of Medicine, University of São Paulo, São Paulo, Brazil.

Muy-Teck Teh (MT)

Centre for Oral Immunobiology and Regenerative Medicine, Institute of Dentistry, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
China-British Joint Molecular Head and Neck Cancer Research Laboratory, Affiliated Stomatological Hospital of Guizhou Medical University, Guiyang, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH